COMP <GO>
RVP vs ABBV // GROSS PROFIT MARGIN
Retractable Technologies Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: RVP 1
— ABBV 9
▲ GROSS PROFIT MARGIN LEADER: ABBV
LAST: $0.58 (-1.15%) • MKT CAP: $17.3M
gross-margins
0.10%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RVP VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RVP | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 0.10% | 70.20% | -70.10 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -23.30% | 29.00% | -52.30 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 3.47% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -55.30% | 24.60% | -79.90 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -32.80% | 6.90% | -39.70 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 15.80% | 8.60% | +7.20 | RVP | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.52 | 5.33 | -4.81 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 22.7 | 65.1 | -42.37 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $17.3M | $513.86B | -$513.84B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RVP REV | ABBV REV | RVP GROSS % | ABBV GROSS % | RVP FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $38.3M | $61.16B | 0.1% | 70.2% | -$7.1M | $17.82B |
| FY 2024 | $33.0M | $56.33B | -3.1% | 70.0% | -$13.0M | $17.83B |
| FY 2023 | $43.6M | $54.32B | — | — | $2.8M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RVP // BETA —
ABBV // BETA 1.15